A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts

Bone

Volumn 51, Issue 3, 2012, Pages 353-361

  Henriksen, Kim ^a   Andreassen, Kim V ^a   Thudium, Christian S ^a,b   Gudmann, Karoline N S ^a   Moscatelli, Ilana ^b   Crüger Hansen, Catherine E ^a   Schulz, Ansgar S ^c   Dziegiel, Morten H ^d   Richter, Johan ^b   Karsdal, Morten A ^a   Neutzsky Wulff, Anita V ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Lund Strategic Center for Stem Cell Biology   (Sweden)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Rigshospitalet   (Denmark)

Author keywords

Coupling; Osteoblasts; Osteoclasts; Osteopetrosis; Resorption inhibitors

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; CTX 1 PROTEIN; DIPROPHYLLINE; ILOMASTAT; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; OSTEOCLAST DIFFERENTIATION FACTOR; PLASTIC; UNCLASSIFIED DRUG;

ARTICLE; BONE; CELL COUNT; CELL METABOLISM; CONTROLLED STUDY; CULTURE MEDIUM; DENTIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE; MONOCYTE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN SECRETION; STEM CELL;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DENTIN; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; TIME FACTORS;

EID: 84863428448     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.06.007     Document Type: Article

References (63)

1. Henriksen K., Neutzsky-Wulff A.V., Bonewald L.F., Karsdal M.A. Local communication on and within bone controls bone remodeling. Bone 2009, 44:1026-1033.
2. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
3. Takahashi H., Epker B., Frost H.M. Resorption precedes formative activity. Surg Forum 1964, 15:437-438.
4. Hattner R., Epker B.N., Frost H.M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965, 206:489-490.
5. Martin T.J., Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005, 11:76-81.
6. Karsdal M.A., Martin T.J., Bollerslev J., Christiansen C., Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res 2007, 22:487-494.
7. Howard G.A., Bottemiller B.L., Turner R.T., Rader J.I., Baylink D.J. Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. Proc Natl Acad Sci U S A 1981, 78:3204-3208.
8. Henriksen K., Bollerslev J., Everts V., Karsdal M.A. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev 2011, 32:31-63.
9. Segovia-Silvestre T., Neutzsky-Wulff A.V., Sorensen M.G., Christiansen C., Bollerslev J., Karsdal M.A., et al. Advances in osteoclast biology resulting from the study of osteopetrotic mutations. Hum Genet 2008, 124:561-577.
10. Alatalo S.L., Ivaska K.K., Waguespack S.G., Econs M.J., Vaananen H.K., Halleen J.M. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004, 50:883-890.
11. Del F.A., Cappariello A., Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008, 42:19-29.
12. Henriksen K., Flores C., Thomsen J.S., Bruel A.M., Thudium C.S., Neutzsky-Wulff A.V., et al. Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength. PLoS One 2011, 6:e27482.
13. Koh A.J., Demiralp B., Neiva K.G., Hooten J., Nohutcu R.M., Shim H., et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 2005, 146:4584-4596.
14. Demiralp B., Chen H.L., Koh A.J., Keller E.T., McCauley L.K. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 2002, 143:4038-4047.
15. Pierroz D.D., Bonnet N., Baldock P.A., Ominsky M.S., Stolina M., Kostenuik P.J., et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010, 285:28164-28173.
16. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., Pangrazio A., Susani L., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
17. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008, 83:64-76.
18. Henriksen K., Leeming D.J., Byrjalsen I., Nielsen Rh., Sorensen M.G., Dziegiel M.H., et al. Osteoclasts prefer aged bone. Osteoporos Int 2007, 18:751-759.
19. Everts V., Korper W., Hoeben K.A., Jansen I.D., Bromme D., Cleutjens K.B., et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006, 21:1399-1408.
20. Everts V., Korper W., Jansen D.C., Steinfort J., Lammerse I., Heera S., et al. Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 1999, 13:1219-1230.
21. Everts V., de Vries T.J., Helfrich M.H. Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. Biochim Biophys Acta 2009, 1792:757-765.
22. Jansen I.D., Mardones P., Lecanda F., de Vries T.J., Recalde S., Hoeben K.A., et al. Ae2a,b-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J 2009, 23:3470-3481.
23. Perez-Amodio S., Jansen D.C., Schoenmaker T., Vogels I.M., Reinheckel T., Hayman A.R., et al. Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity. Calcif Tissue Int 2006, 79:245-254.
24. Nordahl J., Andersson G., Reinholt F.P. Chondroclasts and osteoclasts in bones of young rats: comparison of ultrastructural and functional features. Calcif Tissue Int 1998, 63:401-408.
25. Zenger S., Hollberg K., Ljusberg J., Norgard M., Ek-Rylander B., Kiviranta R., et al. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone 2007, 41:820-832.
26. Azari A., Schoenmaker T., de Souza Faloni A.P., Everts V., de Vries T.J. Jaw and long bone marrow derived osteoclasts differ in shape and their response to bone and dentin. Biochem Biophys Res Commun 2011, 409:205-210.
27. Hollberg K., Marsell R., Norgard M., Larsson T., Jonsson K.B., Andersson G. Osteoclast polarization is not required for degradation of bone matrix in rachitic FGF23 transgenic mice. Bone 2008, 42:1111-1121.
28. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006, 4:111-121.
29. Karsdal M.A., Neutzsky-Wulff A.V., Dziegiel M.H., Christiansen C., Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 2008, 366:483-488.
30. Pederson L., Ruan M., Westendorf J.J., Khosla S., Oursler M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008, 105:20764-20769.
31. Fuller K., Lawrence K.M., Ross J.L., Grabowska U.B., Shiroo M., Samuelsson B., et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008, 42:200-211.
32. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26:242-251.
33. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012, 27:509-523.
34. Way K.J., Dinh H., Keene M.R., White K.E., Clanchy F.I., Lusby P., et al. The generation and properties of human macrophage populations from hemopoietic stem cells. J Leukoc Biol 2009, 85:766-778.
35. Karsdal M.A., Hjorth P., Henriksen K., Kirkegaard T., Nielsen K.L., Lou H., et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 2003, 278:44975-44987.
36. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Helix N., Stahlhut M., et al. The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 2004, 19:1144-1153.
37. Henriksen K., Sorensen M.G., Nielsen Rh., Gram J., Schaller S., Dziegiel M.H., et al. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 2006, 21:58-66.
38. Henriksen K., Gram J., Neutzsky-Wulff A.V., Jensen V.K., Dziegiel M.H., Bollerslev J., et al. Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7. Biochem Biophys Res Commun 2009, 378:804-809.
39. Henriksen K., Gram J., Schaller S., Dahl B.H., Dziegiel M.H., Bollerslev J., et al. Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 2004, 164:1537-1545.
40. Ghosh-Choudhury N., Windle J.J., Koop B.A., Harris M.A., Guerrero D.L., Wozney J.M., et al. Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice. Endocrinology 1996, 137:331-339.
41. Bonewald L.F., Harris S.E., Rosser J., Dallas M.R., Dallas S.L., Camacho N.P., et al. von Kossa staining alone is not sufficient to confirm that mineralization in vitro represents bone formation. Calcif Tissue Int 2003, 72:537-547.
42. Steward C.G., Blair A., Moppett J., Clarke E., Virgo P., Lankester A., et al. High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis. Biol Blood Marrow Transplant 2005, 11:115-121.
43. Taranta A., Migliaccio S., Recchia I., Caniglia M., Luciani M., De Rossi G., et al. Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 2003, 162:57-68.
44. Frattini A., Orchard P.J., Sobacchi C., Giliani S., Abinun M., Mattsson J.P., et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000, 25:343-346.
45. Del Fattore A., Peruzzi B., Rucci N., Recchia I., Cappariello A., Longo M., et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 2006, 43:315-325.
46. Sorensen M.G., Henriksen K., Neutzsky-Wulff A.V., Dziegiel M.H., Karsdal M.A. Diphyllin, a Novel and Naturally Potent V-ATPase Inhibitor, Abrogates Acidification of the Osteoclastic Resorption Lacunae and Bone Resorption. J Bone Miner Res 2007, 22:1640-1648.
47. Neutzsky-Wulff A.V., Sorensen M.G., Kocijancic D., Leeming D.J., Dziegiel M.H., Karsdal M.A., et al. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption-implications for osteoclast quality. BMC Musculoskelet Disord 2010, 11:109.
48. Bollerslev J., Steiniche T., Melsen F., Mosekilde L. Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 1989, 10:19-24.
49. Rzeszutek K., Sarraf F., Davies J.E. Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg 2003, 14:301-307.
50. Karsdal M.A., Henriksen K., Sorensen M.G., Gram J., Schaller S., Dziegiel M.H., et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005, 166:467-476.
51. Andersen T.L., Sondergaard T.E., Skorzynska K.E., Gnaes-Hansen F., Plesner T.L., Hauge E.M., et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009, 174:239-247.
52. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001, 16:1575-1582.
53. Chang M.K., Raggatt L.J., Alexander K.A., Kuliwaba J.S., Fazzalari N.L., Schroder K., et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J Immunol 2008, 181:1232-1244.
54. Pettit A.R., Chang M.K., Hume D.A., Raggatt L.J. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 2008, 43:976-982.
55. Nielsen Rh., Karsdal M.A., Sorensen M.G., Dziegiel M.H., Henriksen K. Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun 2007, 360:834-839.
56. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., et al. Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density. J Bone Miner Res 2010, 25:937-947.
57. Fromigue O., Hay E., Barbara A., Petrel C., Traiffort E., Ruat M., et al. Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med 2009, 13:2189-2199.
58. Del Fattore A., Fornari R., Van W.L., de F.F., Timmermans J.P., Peruzzi B., et al. A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts. J Bone Miner Res 2008, 23:380-391.
59. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
60. Wronski T.J., Yen C.F., Qi H., Dann L.M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993, 132:823-831.
61. Finkelstein J.S., Hayes A., Hunzelman J.L., Wyland J.J., Lee H., Neer R.M. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
62. Visentin L., Dodds R.A., Valente M., Misiano P., Bradbeer J.N., Oneta S., et al. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 2000, 106:309-318.
63. Ramnaraine M.L., Mathews W.E., Clohisy D.R. Lentivirus transduction of human osteoclast precursor cells and differentiation into functional osteoclasts. Bone 2011, 50:97-103.